Dune gets FDA panel nod for breast cancer detector

Maryland's Dune Medical Devices won a 10-1 vote from an FDA advisory panel on MarginProbe, the company's breast cancer surgery aid. The device is designed to minimize the need for repeat operations after breast-conservation surgeries by detecting the presence of cancer at or near the surface of excised tissue. In a trial of 600 patients, Dune found that MarginProbe significantly reduced the rate of follow-up surgeries, the company said. The device is already available in Europe, and, after filing a PMA with the FDA in 2011, the company expects to get MarginProbe on U.S. shelves soon. Release | More

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.